Literature DB >> 23557861

The efficacy of nuclease-resistant Chol-siRNA in primary breast tumors following complexation with PLL-PEG(5K).

Vishakha V Ambardekar1, Rajesh R Wakaskar, Bhawna Sharma, Joy Bowman, Willy Vayaboury, Rakesh K Singh, Joseph A Vetro.   

Abstract

Modifying the sense strand of nuclease-resistant siRNA with 3'-cholesterol (Chol-*siRNA) increases mRNA suppression after i.v. administration but with relatively low efficacy. We previously found evidence in vitro that suggests complexation of Chol-siRNA with PLL-PEG(5K), a block copolymer of poly-l-lysine and 5 kDa polyethylene glycol, may increase the efficacy of Chol-siRNA in vivo in a PLL block length-dependent manner. In this study, the extent that polyplexes of PLL10-PEG(5K), PLL30-PEG(5K), and PLL50-PEG(5K) protect complexed Chol-siRNA in high concentrations of murine serum and affect the activity of Chol-*siRNA in murine 4T1 breast tumor epithelial cells in vitro and in primary orthotopic tumors of 4T1 was compared. PLL-PEG(5K) required 3'-Chol to protect full-length siRNA from nuclease degradation in 90% (v/v) murine serum and protection was increased by increasing PLL block length and nuclease resistance of Chol-siRNA. Polyplexes of Chol-*siLuc suppressed stably expressed luciferase in 4T1-Luc cells to different levels in vitro where PLL30 > PLL50 > PLL10. In contrast, only polyplexes of Chol-*siLuc and PLL30-PEG(5K) or PLL50-PEG(5K) suppressed high levels of luciferase in primary orthotopic tumors of 4T1-Luc after i.v. administration, whereas polyplexes of Chol-*siLuc and PLL10-PEG(5K), inactive Chol-*siCtrl polyplexes of PLL-PEG(5K), or Chol-*siLuc alone had no detectable activity. As a whole, these results indicate that polyplexes of PLL-PEG(5K) increase the efficacy of nuclease-resistant Chol-siRNA in primary breast tumors after i.v. administration in a PLL block length-dependent manner. Thus, complexation of Chol-siRNA with PLL-PEG(5K) may be a promising approach to increase the efficacy of Chol-siRNA in a wide range of primary tumors, metastases, and other tissues but likely requires a PLL block length that balances polymer-related adverse effects, Chol-siRNA bioavailability, and subsequent activity in the target cell.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23557861      PMCID: PMC3649532          DOI: 10.1016/j.biomaterials.2013.03.021

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  24 in total

Review 1.  Unlocking the potential of the human genome with RNA interference.

Authors:  Gregory J Hannon; John J Rossi
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

2.  Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum.

Authors:  Jörg Haupenthal; Christina Baehr; Simone Kiermayer; Stefan Zeuzem; Albrecht Piiper
Journal:  Biochem Pharmacol       Date:  2006-01-10       Impact factor: 5.858

3.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

Authors:  David V Morrissey; Jennifer A Lockridge; Lucinda Shaw; Karin Blanchard; Kristi Jensen; Wendy Breen; Kimberly Hartsough; Lynn Machemer; Susan Radka; Vasant Jadhav; Narendra Vaish; Shawn Zinnen; Chandra Vargeese; Keith Bowman; Chris S Shaffer; Lloyd B Jeffs; Adam Judge; Ian MacLachlan; Barry Polisky
Journal:  Nat Biotechnol       Date:  2005-07-24       Impact factor: 54.908

4.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

5.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

Review 6.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.

Authors:  H Maeda; J Wu; T Sawa; Y Matsumura; K Hori
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

7.  Stabilization of poly-L-lysine/DNA polyplexes for in vivo gene delivery to the liver.

Authors:  D Y Kwoh; C C Coffin; C P Lollo; J Jovenal; M G Banaszczyk; P Mullen; A Phillips; A Amini; J Fabrycki; R M Bartholomew; S W Brostoff; D J Carlo
Journal:  Biochim Biophys Acta       Date:  1999-02-16

Review 8.  RNA interference therapeutics for cancer: challenges and opportunities (review).

Authors:  Roop Singh Bora; Dikshi Gupta; Trilochan Kanwaljit Singh Mukkur; Kulvinder Singh Saini
Journal:  Mol Med Rep       Date:  2012-04-18       Impact factor: 2.952

9.  Effect of albumin and polyanion on the structure of DNA complexes with polycation containing hydrophilic nonionic block.

Authors:  D Oupický; C Konák; P R Dash; L W Seymour; K Ulbrich
Journal:  Bioconjug Chem       Date:  1999 Sep-Oct       Impact factor: 4.774

10.  Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging.

Authors:  Derek W Bartlett; Mark E Davis
Journal:  Nucleic Acids Res       Date:  2006-01-12       Impact factor: 16.971

View more
  6 in total

1.  Conjugation and Evaluation of Small Hydrophobic Molecules to Triazole-Linked siRNAs.

Authors:  Brandon J Peel; Gordon Hagen; Kalaivani Krishnamurthy; Jean-Paul Desaulniers
Journal:  ACS Med Chem Lett       Date:  2014-12-04       Impact factor: 4.345

2.  Complexation of Chol-DsiRNA in place of Chol-siRNA greatly increases the duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) in primary murine syngeneic breast tumors after i.v. administration.

Authors:  Vishakha V Ambardekar; Rajesh R Wakaskar; Zhen Ye; Stephen M Curran; Timothy R McGuire; Don W Coulter; Rakesh K Singh; Joseph A Vetro
Journal:  Int J Pharm       Date:  2018-03-27       Impact factor: 5.875

3.  Peripherally cross-linking the shell of core-shell polymer micelles decreases premature release of physically loaded combretastatin A4 in whole blood and increases its mean residence time and subsequent potency against primary murine breast tumors after IV administration.

Authors:  Rajesh R Wakaskar; Sai Praneeth R Bathena; Shailendra B Tallapaka; Vishakha V Ambardekar; Nagsen Gautam; Rhishikesh Thakare; Samantha M Simet; Stephen M Curran; Rakesh K Singh; Yuxiang Dong; Joseph A Vetro
Journal:  Pharm Res       Date:  2014-09-16       Impact factor: 4.200

4.  Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer.

Authors:  Zhen Ye; Mai Mohamed Abdelmoaty; Vishakha V Ambardekar; Stephen M Curran; Shetty Ravi Dyavar; Lora L Arnold; Samuel M Cohen; Devendra Kumar; Yazen Alnouti; Don W Coulter; Rakesh K Singh; Joseph A Vetro
Journal:  Nanomedicine       Date:  2021-02-03       Impact factor: 5.307

Review 5.  Peptides used in the delivery of small noncoding RNA.

Authors:  Ravi S Shukla; Bin Qin; Kun Cheng
Journal:  Mol Pharm       Date:  2014-09-08       Impact factor: 4.939

6.  Direct Comparison of Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes Targeting STAT3 in a Syngeneic Murine Model of TNBC.

Authors:  Zhen Ye; Mai Mohamed Abdelmoaty; Stephen M Curran; Shetty Ravi Dyavar; Devendra Kumar; Yazen Alnouti; Don W Coulter; Anthony T Podany; Rakesh K Singh; Joseph A Vetro
Journal:  Noncoding RNA       Date:  2022-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.